Anika Therapeutics Inc ANIK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sidoti Events, LLC's Virtual August Micro-Cap Conference
-
Anika Reports Second Quarter 2024 Financial Results
-
Anika to Participate in the Sidoti Virtual Investor Conference
-
Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024
-
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 80.71
- Price/Sales
- 2.20
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.37%
Company Profile
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 357
- Website
- https://www.anika.com
Comparables
Valuation
|
Metric
|
ANIK
|
ATEC
|
AXNX
|
|---|---|---|---|
Price/Earnings (Normalized) | 80.71 | — | 604.07 |
Price/Book Value | 1.77 | 43.32 | 5.51 |
Price/Sales | 2.20 | 1.31 | 8.52 |
Price/Cash Flow | 18.11 | — | 110.45 |
Price/Earnings
ANIK
ATEC
AXNX
Financial Strength
|
Metric
|
ANIK
|
ATEC
|
AXNX
|
|---|---|---|---|
Quick Ratio | 3.70 | 1.08 | 7.01 |
Current Ratio | 5.93 | 2.22 | 8.96 |
Interest Coverage | — | −8.06 | — |
Quick Ratio
ANIK
ATEC
AXNX
Profitability
|
Metric
|
ANIK
|
ATEC
|
AXNX
|
|---|---|---|---|
Return on Assets (Normalized) | 2.40% | −9.32% | 5.50% |
Return on Equity (Normalized) | 2.97% | −562.13% | 6.16% |
Return on Invested Capital (Normalized) | 1.92% | −8.81% | 3.86% |
Return on Assets
ANIK
ATEC
AXNX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Ljjkcnjwd | Vqqlv | $87.2 Bil | |||
| Merck KGaA ADR
MKKGY
| Zhdvhghmb | Qnmvh | $75.7 Bil | |||
| Haleon PLC ADR
HLN
| Fqsrqhhmk | Qwkx | $47.3 Bil | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Qnqydhz | Gnktg | $20.0 Bil | |||
| Viatris Inc
VTRS
| Xhjndvzs | Wsj | $13.7 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Mysjpjcyx | Vqbs | $13.4 Bil | |||
| Catalent Inc
CTLT
| Hdbywcfyn | Xnqtsqd | $11.0 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Xlnpfvt | Yvllb | $3.5 Bil | |||
| Perrigo Co PLC
PRGO
| Qbcrcqpbm | Pbbw | $3.4 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Wsrgplnhm | Wlsx | $2.4 Bil |
United States